1. Home
  2. EU vs MYGN Comparison

EU vs MYGN Comparison

Compare EU & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo enCore Energy Corp.

EU

enCore Energy Corp.

HOLD

Current Price

$2.22

Market Cap

464.5M

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$4.90

Market Cap

429.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EU
MYGN
Founded
2009
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
464.5M
429.7M
IPO Year
2011
1996

Fundamental Metrics

Financial Performance
Metric
EU
MYGN
Price
$2.22
$4.90
Analyst Decision
Strong Buy
Hold
Analyst Count
1
9
Target Price
$4.00
$8.06
AVG Volume (30 Days)
3.0M
1.2M
Earning Date
01-01-0001
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$58,334,000.00
$771,400,000.00
Revenue This Year
$17.41
$7.26
Revenue Next Year
$95.45
$5.09
P/E Ratio
N/A
N/A
Revenue Growth
163.38
2.33
52 Week Low
$1.01
$3.76
52 Week High
$4.19
$11.44

Technical Indicators

Market Signals
Indicator
EU
MYGN
Relative Strength Index (RSI) 32.79 46.96
Support Level $1.54 $4.82
Resistance Level $2.56 $5.67
Average True Range (ATR) 0.19 0.37
MACD -0.04 0.10
Stochastic Oscillator 12.00 50.62

Price Performance

Historical Comparison
EU
MYGN

About EU enCore Energy Corp.

enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: